Cancer Biotech Day One Biopharma Expands to ADCs, Paying $55M to Nab a Phase 1-Ready Drug
Day One Biopharmaceuticals is adding an antibody drug conjugate to its pipeline, licensing rights to a molecule from MabCare Therapeutics. The MabCare ADC addresses PTK7, a protein found in many types of solid tumors.